# G-PUR® for Reduced Lead Bioavailability

> **NCT04138693** · NA · COMPLETED · sponsor: **Glock Health, Science and Research GmbH** · enrollment: 42 (actual)

## Conditions studied

- Lead Exposure

## Interventions

- **DEVICE:** G-PUR® 2x 2.0 g oral suspension
- **DEVICE:** G-PUR® 1x 2.0 g oral suspension
- **DEVICE:** Placebo oral suspension

## Key facts

- **NCT ID:** NCT04138693
- **Lead sponsor:** Glock Health, Science and Research GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-24
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-02-12
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2020-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04138693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04138693, "G-PUR® for Reduced Lead Bioavailability". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04138693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*